Vancomycin Oral Capsule

DRUG7 trials

Conditions

Bone Marrow TransplantClostridioides Difficile InfectionClostridium Difficile InfectionColitis, UlcerativeColorectal CancerGastric CancerGastroesophageal Junction AdenocarcinomaHCC - Hepatocellular Carcinoma

Phase 1

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

CompletedNCT03827447

Medical College of WisconsinClostridium Difficile Infection

Start: 2019-07-17End: 2021-06-30Updated: 2021-10-20

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

CompletedNCT04208958

Vedanta Biosciences, Inc.Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma +2

Start: 2020-01-23End: 2023-02-23Updated: 2025-10-27

Clostridioides Difficile Colonisation

NCT05693077

Leiden University Medical CenterClostridioides Difficile Infection

Start: 2023-09-22End: 2025-06-30Target: 70Updated: 2023-10-17

Phase 2

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

CompletedNCT03030248

Medical College of WisconsinBone Marrow Transplant, Clostridium Difficile Infection, Hematologic Diseases +1

Start: 2018-06-01End: 2020-06-30Updated: 2020-09-10

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

TerminatedNCT05370885

Vedanta Biosciences, Inc.Colitis, Ulcerative, Ulcerative Colitis

Start: 2023-05-08End: 2025-08-29Updated: 2025-12-17

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

RecruitingNCT05690048

Michael DillHCC - Hepatocellular Carcinoma, Immunotherapy

Start: 2025-07-16End: 2028-03-31Target: 48Updated: 2025-08-06

Phase 4

Antibiotics and Vaccine Immune Responses Study

RecruitingNCT06148025

South Australian Health and Medical Research InstituteVaccine Response Impaired

Start: 2023-11-23End: 2028-10-01Target: 348Updated: 2025-12-10

Related Papers

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

BMJ Open2025-09-012 citations

Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers